Ricolinostat

Drug Profile

Ricolinostat

Alternative Names: ACY-1215; ACY-63; Rocilinostat

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Columbia University; Dana-Farber Cancer Institute; Massachusetts General Hospital; Regenacy Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Lymphoma
  • Phase I Breast cancer; Chronic lymphocytic leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Peripheral nervous system diseases

Most Recent Events

  • 17 Mar 2017 Regenacy Pharmaceuticals plans a phase II trial for Polycystic kidney disease
  • 17 Mar 2017 Regenacy Pharmaceuticals plans a phase II trial for Diabetic neuropathies
  • 17 Mar 2017 Regenacy Pharmaceuticals plans phase II trials for Peripheral neuropathies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top